FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5 obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Parini Michael (Last) (First) (Middle) 50 NORTHERN AVENUE (Street) BOSTON MA 02210						2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX] 3. Date of Earliest Transaction (Month/Day/Year) 05/03/2019 4. If Amendment, Date of Original Filed (Month/Day/Year)								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) EVP, CL&AO 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S		(Zip)				1 6350													
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/*)					on	2A. Deemed Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an		I (A) or	5. Amount		int of es ially Following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
								ĺ	Code	v	Amount	(A) or (D)	Price		Transac (Instr. 3	tion(s)	on(s)		(Instr. 4)	
Common	05/03/2019					M		2,329	A	\$80	6.52	37	7,332		D					
Comon S	05/03/2019					S ⁽¹⁾		500	D	\$170.	33(2)(3) 36		,832		D					
Common	05/03/2019					S ⁽¹⁾		500	D	\$171.	71.71 ⁽³⁾⁽⁴⁾		6,332		D					
Common Stock 05/3)19				S ⁽¹⁾		707	D	\$17	\$173 ⁽³⁾⁽⁵⁾		35,625		D		
Common Stock 05/03/201)19	9			S ⁽¹⁾		622	D	\$173.72(3)(6)		35,003			D		
		Т	able								sposed of				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	eemed Ition Date,	4. Transa Code (action	5. Number		6. Dat Expir (Mont		ccisable and clate (Year)	7. Title and Amount of Securities Underlying Derivative Sect (Instr. 3 and 4)		8. D S (I	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owne Form Direct or Ind (I) (In:	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
Stock					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	of Sha	res						
Option (Right to	\$86.52	05/03/2019			M		2,329			(7)	02/02/2027	Commo		329	\$0.00	16,310		D		

Explanation of Responses:

- 1. Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$170.33 (range \$169.96 to \$170.63).
- 3. Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Open market sales reported on this line occurred at a weighted average price of \$171.71 (range \$171.35 to \$172.16).
- 5. Open market sales reported on this line occurred at a weighted average price of \$173.00 (range \$172.54 to \$173.39).
- 6. Open market sales reported on this line occurred at a weighted average price of \$173.72 (range \$173.55 to \$173.91).
- 7. The option vests in 16 quarterly installments from 02/03/2017.

Remarks:

/s/ Omar White, Attorney-in-Fact

05/06/2019

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.